Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies

Cancer(2021)10.1002/cncr.33433Source: DataRank Database

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies is a research paper published in Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 31 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: bronzeTopics (20)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Azam Ghafoor,Manjistha Sengupta ORCID,Raffit Hassan ORCID,Zishuo I. Hu

Live enrichment

PubMed:33620732 PMC:PMC8555868

Intramural NIH HHS

Grant: Z01 BC006150

Intramural NIH HHS

Grant: Z01 BC010816

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33433

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33433

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cncr.33433

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33433

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8555868

MeSH Terms

HumansPleural NeoplasmsImmunotherapy, AdoptiveDrug Therapy, CombinationRandomized Controlled Trials as TopicGPI-Linked ProteinsMolecular Targeted TherapyAntibodies, Monoclonal, HumanizedIpilimumabReceptors, Chimeric AntigenNivolumabMesothelioma, MalignantImmune Checkpoint InhibitorsMesothelin

Keywords

ImmunotherapyMesotheliomaMesothelinChimeric Antigen Receptor T Cells (Car T Cells)Cytotoxic T-lymphocyte-associated Protein 4 (Ctla-4) InhibitorProgrammed Cell Death-1/programmed Cell Death Ligand-1 (Pd-1/pd-l1) Inhibitor

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies

FAIR Checklist

Authors (4)

Funding (2 grants)

Open Access

Topics

Annotations (Europe PMC)